{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:00:11Z","timestamp":1790305211861,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.autrev.2018.01.021","type":"journal-article","created":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T06:36:35Z","timestamp":1525329395000},"page":"703-708","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"title":["Inflammation and atherosclerosis: Cardiovascular evaluation in patients with autoimmune diseases"],"prefix":"10.1016","volume":"17","author":[{"given":"Ricardo O.","family":"Esc\u00e1rcega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Lipinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Garc\u00eda-Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Mendoza-Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Galvez-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Cervera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2018.01.021_bb0005","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.autrev.2006.07.001","article-title":"Insulin resistance, chronic inflammatory state and the link with systemic lupus erythematosus-related coronary disease","volume":"6","author":"Escarcega","year":"2006","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.021_bb0010","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1161\/01.ATV.0000079512.66448.1D","article-title":"C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME study","volume":"23","author":"Luc","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.autrev.2018.01.021_bb0015","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/0961203308101435","article-title":"Accelerated atherosclerosis in systemic lupus erythematosus: perspectives towards decreasing cardiovascular morbidity and mortality","volume":"18","author":"Escarcega","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2018.01.021_bb0020","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1001\/jama.1987.03400090067035","article-title":"Fibrinogen and risk of cardiovascular disease. The Framingham study","volume":"258","author":"Kannel","year":"1987","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2018.01.021_bb0025","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.autrev.2015.03.002","article-title":"Neutrophil extracellular traps and their role in the development of chronic inflammation and autoimmunity","volume":"14","author":"Pinegin","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.021_bb0030","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.autrev.2017.09.012","article-title":"Neutrophil extracellular traps (NETs) in autoimmune diseases: a comprehensive review","volume":"16","author":"Lee","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.021_bb0035","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.autrev.2017.07.009","article-title":"Effects of interleukin 17 on the cardiovascular system","volume":"16","author":"Robert","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.021_bb0040","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2018.01.021_bb0045","doi-asserted-by":"crossref","first-page":"E58","DOI":"10.1002\/clc.20462","article-title":"Serial analyses of C-reactive protein and myeloperoxidase in acute coronary syndrome","volume":"32","author":"Borges","year":"2009","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.autrev.2018.01.021_bb0050","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1161\/ATVBAHA.111.223768","article-title":"Association between obesity, high-sensitivity C-reactive protein \u22652\u202fmg\/L, and subclinical atherosclerosis: implications of JUPITER from the Multi-Ethnic Study of Atherosclerosis","volume":"31","author":"Blaha","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.autrev.2018.01.021_bb0055","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2018.01.021_bb0060","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1749-6632.1989.tb23998.x","article-title":"IFN beta 2\/BSF2\/IL-6 is the monocyte-derived HSF that regulates receptor-specific acute phase gene regulation in hepatocytes","volume":"557","author":"Gauldie","year":"1989","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2018.01.021_bb0065","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1042\/bj2650621","article-title":"Interleukin-6 and the acute phase response","volume":"265","author":"Heinrich","year":"1990","journal-title":"Biochem J"},{"key":"10.1016\/j.autrev.2018.01.021_bb0070","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1161\/01.CIR.101.15.1767","article-title":"Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men","volume":"101","author":"Ridker","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2018.01.021_bb0075","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13098-017-0266-5","article-title":"Elevated serum interleukin-6 is predictive of coronary artery disease in intermediate risk overweight patients referred for coronary angiography","volume":"9","author":"Wainstein","year":"2017","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.autrev.2018.01.021_bb0080","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/01.CIR.0000158479.58589.0A","article-title":"Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein","volume":"111","author":"Maier","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2018.01.021_bb0085","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1093\/eurheartj\/ehu203","article-title":"Anti-inflammatory therapies for cardiovascular disease","volume":"35","author":"Ridker","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.autrev.2018.01.021_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011765","article-title":"Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation","volume":"5","author":"Rajamaki","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2018.01.021_bb0095","first-page":"937","article-title":"Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis","volume":"34","author":"Aubry","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.021_bb0100","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1136\/annrheumdis-2016-211066","article-title":"Acute coronary syndrome in new-onset rheumatoid arthritis: a population-based nationwide cohort study of time trends in risks and excess risks","volume":"76","author":"Holmqvist","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.01.021_bb0105","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1093\/eurheartj\/ehv461","article-title":"Rheumatoid arthritis is associated with a more severe presentation of acute coronary syndrome and worse short-term outcome","volume":"36","author":"Mantel","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.autrev.2018.01.021_bb0110","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.autrev.2016.07.026","article-title":"Cardiovascular risk assessment in patients with rheumatoid arthritis: the relevance of clinical, genetic and serological markers","volume":"15","author":"Lopez-Mejias","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.021_bb0115","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.autrev.2016.03.014","article-title":"Autoimmune atherosclerosis in 3D: how it develops, how to diagnose and what to do","volume":"15","author":"Szekanecz","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.021_bb0120","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1136\/ard.62.7.607","article-title":"Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome","volume":"62","author":"Medina","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.01.021_bb0125","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.autrev.2014.11.003","article-title":"Antiphospholipid syndrome and the heart: a case series and literature review","volume":"14","author":"Denas","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.021_bb0130","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/oxfordjournals.aje.a009122","article-title":"Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study","volume":"145","author":"Manzi","year":"1997","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.autrev.2018.01.021_bb0135","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s12026-016-8884-9","article-title":"Association between ischemic heart disease and systemic lupus erythematosus-a large case-control study","volume":"65","author":"Watad","year":"2017","journal-title":"Immunol Res"},{"key":"10.1016\/j.autrev.2018.01.021_bb0140","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.autrev.2017.01.009","article-title":"Subclinical atherosclerosis in systemic lupus erythematosus: comparable risk with diabetes mellitus and rheumatoid arthritis","volume":"16","author":"Tektonidou","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.021_bb0145","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.autrev.2015.10.002","article-title":"Subclinical atherosclerosis in patients with systemic lupus erythematosus: a systemic review and meta-analysis","volume":"15","author":"Wu","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.021_bb0150","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00005792-199905000-00003","article-title":"Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus","volume":"78","author":"Cervera","year":"1999","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2018.01.021_bb0155","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00005792-199209000-00004","article-title":"Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices","volume":"71","author":"Petri","year":"1992","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2018.01.021_bb0160","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1002\/art.11296","article-title":"Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study","volume":"48","author":"Bruce","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.01.021_bb0165","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.autrev.2015.08.007","article-title":"Systemic lupus erythematosus and atherosclerosis: review of the literature","volume":"15","author":"Frieri","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.021_bb0170","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1161\/01.RES.0000163635.62927.34","article-title":"Adipose tissue, inflammation, and cardiovascular disease","volume":"96","author":"Berg","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.autrev.2018.01.021_bb0175","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1042\/CS20170098","article-title":"Cytokines of the IL-1 family: recognized targets in chronic inflammation underrated in organ transplantations","volume":"131","author":"Striz","year":"2017","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.autrev.2018.01.021_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1003470","article-title":"The structural pathway of interleukin 1 (IL-1) initiated signaling reveals mechanisms of oncogenic mutations and SNPs in inflammation and cancer","volume":"10","author":"Acuner Ozbabacan","year":"2014","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.autrev.2018.01.021_bb0185","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2018.01.021_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5152\/tpa.2015.2229","article-title":"Treatment in juvenile rheumatoid arthritis and new treatment options","volume":"50","author":"Kasapcopur","year":"2015","journal-title":"Turk Pediatri Ars"},{"key":"10.1016\/j.autrev.2018.01.021_bb0195","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.semarthrit.2017.06.006","article-title":"Adult onset Still's disease-the evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review)","volume":"47","author":"Junge","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.01.021_bb0200","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jamadermatol.2017.2392","article-title":"Canakinumab for severe hidradenitis suppurativa: preliminary experience in 2 cases","volume":"153","author":"Houriet","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.autrev.2018.01.021_bb0205","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/1744666X.2017.1313116","article-title":"Canakinumab for the treatment of familial Mediterranean fever","volume":"13","author":"Ozdogan","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.autrev.2018.01.021_bb0210","first-page":"388","article-title":"Autoinflammation: canakinumab effective in HIDS treatment","volume":"13","author":"Ummarino","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.021_bb0215","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10067-016-3506-4","article-title":"Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behcet's disease-related uveitis: a multicenter retrospective observational study","volume":"36","author":"Fabiani","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.021_bb0220","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1093\/eurheartj\/ehr373","article-title":"Antiplatelet agents for the treatment and prevention of atherothrombosis","volume":"32","author":"Patrono","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.autrev.2018.01.021_bb0225","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.autrev.2018.01.021_bb0230","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/CIR.0000000000000230","article-title":"Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association","volume":"132","author":"Fox","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2018.01.021_bb0235","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/M16-0577","article-title":"Aspirin use for the primary prevention of cardiovascular disease and colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement","volume":"164","author":"Bibbins-Domingo","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2018.01.021_bb0240","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Antithrombotic Trialists","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2018.01.021_bb0245","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.jacc.2017.08.037","article-title":"Antiplatelet agents for the treatment and prevention of coronary atherothrombosis","volume":"70","author":"Patrono","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.autrev.2018.01.021_bb0250","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2012.07.013","volume":"60","author":"Fihn","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.autrev.2018.01.021_bb0255","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3899\/jrheum.161351","article-title":"Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus","volume":"44","author":"Fasano","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.021_bb0260","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1093\/rheumatology\/kew231","article-title":"Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study","volume":"55","author":"Iudici","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2018.01.021_bb0265","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2018.01.021_bb0270","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s12026-013-8409-8","article-title":"Statins and autoimmunity","volume":"56","author":"Khattri","year":"2013","journal-title":"Immunol Res"},{"key":"10.1016\/j.autrev.2018.01.021_bb0275","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.autrev.2018.01.021_bb0280","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/0961203307076519","article-title":"Lack of subclinical myocardial ischaemia in Mexican patients with systemic lupus erythematosus without traditional risk factors for coronary artery disease","volume":"16","author":"Garcia-Carrasco","year":"2007","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2018.01.021_bb0285","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1161\/CIRCULATIONAHA.106.178458","volume":"114","author":"Budoff","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2018.01.021_bb0290","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jacc.2008.07.072","article-title":"Coronary calcium predicts events better with absolute calcium scores than age-sex-race\/ethnicity percentiles: MESA (Multi-Ethnic Study of Atherosclerosis)","volume":"53","author":"Budoff","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.autrev.2018.01.021_bb0295","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.117.006592","article-title":"Coronary artery calcium distribution is an independent predictor of incident major coronary heart disease events: results from the Framingham heart study","volume":"10","author":"Ferencik","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.autrev.2018.01.021_bb0300","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1093\/rheumatology\/kev198","article-title":"Coronary calcification in SLE: comparison with the Multi-Ethnic Study of Atherosclerosis","volume":"54","author":"Kiani","year":"2015","journal-title":"Rheumatology (Oxford)"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997218301101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997218301101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T19:27:39Z","timestamp":1529609259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997218301101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S1568997218301101"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2018.01.021","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammation and atherosclerosis: Cardiovascular evaluation in patients with autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2018.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}